{"id":{"repo_id":"eiu","oai_identifier":"oai:thekeep.eiu.edu:theses-1932"},"canonical_url":"https://search.ndltd.org/etd/eiu/oai:thekeep.eiu.edu:theses-1932","repository":{"repo_id":"eiu","name":"Eastern Illinois University","base_url":"https://thekeep.eiu.edu/do/oai/"},"display":{"title":"Nonaqueous platination for synthesis of platinated 7 alpha-substituted estradiol","abstract":"Cisplatin, carboplatin, and oxaliplatin are used clinically for treating some cancers, but are they are not the preferred treatment for breast cancer. The usefulness of these platinum-containing drugs is limited by poor concentration of the active platinum moiety within the tumor before dose-limiting side effects are reached. One way to selectively concentrate a platinum antitumor compound in breast cancer cells is to conjugate the platinum moiety via a malonate linkage to an estrogen which selectively binds to the estrogen receptor (ER) protein. The major obstacle to linking a lipophilic estrogen to a diamino-platinum compound is the lack of solubility of estrogens in water, the typical solvent for malonate platination reactions. The development of a nonaqueous platination method was explored with two simple malonic acid derivatives that served as models of an estrogen. model compounds were characterized by ¹H NMR, 13C NMR, IR, mass spectrometry, and elemental analysis. In DMF solution, the models were successfully coordinated to either a diaminoplatinum(II) and trans-1,2- diaminocyclohexaneplatinum(II) species. Each model complex was characterized by at least three of the following techniques: 1H NMR, 13C NMR, The 195pt NMR, mass spectrometry, and elemental analysis. The developed nonaqueous platination method was applied to synthesis of a platinated estrogen. The DACH platinated estrogen was characterized by ¹H NMR, 195Pt NMR, mass spectrometry, and elemental analysis. The cisdimainoplatinated estrogen was characterized by mass spectrometry.","abstract_html":"Cisplatin, carboplatin, and oxaliplatin are used clinically for treating some cancers, but are they are not the preferred treatment for breast cancer. The usefulness of these platinum-containing drugs is limited by poor concentration of the active platinum moiety within the tumor before dose-limiting side effects are reached. One way to selectively concentrate a platinum antitumor compound in breast cancer cells is to conjugate the platinum moiety via a malonate linkage to an estrogen which selectively binds to the estrogen receptor (ER) protein. The major obstacle to linking a lipophilic estrogen to a diamino-platinum compound is the lack of solubility of estrogens in water, the typical solvent for malonate platination reactions. The development of a nonaqueous platination method was explored with two simple malonic acid derivatives that served as models of an estrogen. model compounds were characterized by ¹H NMR, 13C NMR, IR, mass spectrometry, and elemental analysis. In DMF solution, the models were successfully coordinated to either a diaminoplatinum(II) and trans-1,2- diaminocyclohexaneplatinum(II) species. Each model complex was characterized by at least three of the following techniques: 1H NMR, 13C NMR, The 195pt NMR, mass spectrometry, and elemental analysis. The developed nonaqueous platination method was applied to synthesis of a platinated estrogen. The DACH platinated estrogen was characterized by ¹H NMR, 195Pt NMR, mass spectrometry, and elemental analysis. The cisdimainoplatinated estrogen was characterized by mass spectrometry.","abstract_has_math":false,"creators":["Mazzella, Sarah A."],"institution":null,"degree_name":"Master of Science (MS)","degree_level":null,"degree_discipline":"Chemistry and Biochemistry","degree_department":null,"school":null,"contributors":["Robert Chesnut","Richard Keiter","Edward Treadwell"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":null,"date_issued":"","date_published":null,"updated_at":"2026-11-19T07:55:27Z","subjects":["Chemistry"],"languages":[],"rights":[],"rights_urls":["http://creativecommons.org/licenses/by-nc-nd/3.0/"],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://thekeep.eiu.edu/theses/933","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://thekeep.eiu.edu/theses/933","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://thekeep.eiu.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Athekeep.eiu.edu%3Atheses-1932","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Robert Chesnut","Richard Keiter","Edward Treadwell"]},{"key":"dc:creator","label":"Author","values":["Mazzella, Sarah A."]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2012-03-09T08:00:00Z"]},{"key":"dc:date.created","label":"Dc Date Created","values":["2005-01-01T08:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Chemistry and Biochemistry"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science (MS)"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Chemistry"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:rights.license","label":"Dc Rights License","values":["http://creativecommons.org/licenses/by-nc-nd/3.0/"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://thekeep.eiu.edu/theses/933"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Cisplatin, carboplatin, and oxaliplatin are used clinically for treating some cancers, but are they are not the preferred treatment for breast cancer. The usefulness of these platinum-containing drugs is limited by poor concentration of the active platinum moiety within the tumor before dose-limiting side effects are reached. One way to selectively concentrate a platinum antitumor compound in breast cancer cells is to conjugate the platinum moiety via a malonate linkage to an estrogen which selectively binds to the estrogen receptor (ER) protein. The major obstacle to linking a lipophilic estrogen to a diamino-platinum compound is the lack of solubility of estrogens in water, the typical solvent for malonate platination reactions. The development of a nonaqueous platination method was explored with two simple malonic acid derivatives that served as models of an estrogen. model compounds were characterized by ¹H NMR, 13C NMR, IR, mass spectrometry, and elemental analysis. In DMF solution, the models were successfully coordinated to either a diaminoplatinum(II) and trans-1,2- diaminocyclohexaneplatinum(II) species. Each model complex was characterized by at least three of the following techniques: 1H NMR, 13C NMR, The 195pt NMR, mass spectrometry, and elemental analysis. The developed nonaqueous platination method was applied to synthesis of a platinated estrogen. The DACH platinated estrogen was characterized by ¹H NMR, 195Pt NMR, mass spectrometry, and elemental analysis. The cisdimainoplatinated estrogen was characterized by mass spectrometry."]},{"key":"dc:title","label":"Title","values":["Nonaqueous platination for synthesis of platinated 7 alpha-substituted estradiol"]}]}],"canonical_facts":{"dc:contributor":["Robert Chesnut","Richard Keiter","Edward Treadwell"],"dc:creator":["Mazzella, Sarah A."],"dc:date.available":["2012-03-09T08:00:00Z"],"dc:date.created":["2005-01-01T08:00:00Z"],"dc:description.abstract":["Cisplatin, carboplatin, and oxaliplatin are used clinically for treating some cancers, but are they are not the preferred treatment for breast cancer. The usefulness of these platinum-containing drugs is limited by poor concentration of the active platinum moiety within the tumor before dose-limiting side effects are reached. One way to selectively concentrate a platinum antitumor compound in breast cancer cells is to conjugate the platinum moiety via a malonate linkage to an estrogen which selectively binds to the estrogen receptor (ER) protein. The major obstacle to linking a lipophilic estrogen to a diamino-platinum compound is the lack of solubility of estrogens in water, the typical solvent for malonate platination reactions. The development of a nonaqueous platination method was explored with two simple malonic acid derivatives that served as models of an estrogen. model compounds were characterized by ¹H NMR, 13C NMR, IR, mass spectrometry, and elemental analysis. In DMF solution, the models were successfully coordinated to either a diaminoplatinum(II) and trans-1,2- diaminocyclohexaneplatinum(II) species. Each model complex was characterized by at least three of the following techniques: 1H NMR, 13C NMR, The 195pt NMR, mass spectrometry, and elemental analysis. The developed nonaqueous platination method was applied to synthesis of a platinated estrogen. The DACH platinated estrogen was characterized by ¹H NMR, 195Pt NMR, mass spectrometry, and elemental analysis. The cisdimainoplatinated estrogen was characterized by mass spectrometry."],"dc:identifier":["https://thekeep.eiu.edu/theses/933"],"dc:rights.license":["http://creativecommons.org/licenses/by-nc-nd/3.0/"],"dc:subject":["Chemistry"],"dc:title":["Nonaqueous platination for synthesis of platinated 7 alpha-substituted estradiol"],"thesis:degree_discipline":["Chemistry and Biochemistry"],"thesis:degree_name":["Master of Science (MS)"]},"updated_at":"2026-11-19T07:55:27Z"}